Becton Dickinson (BDX) In-Depth Stock Report
A medical technology company built on syringes, infusion, and diagnostics, priced on portfolio simplification and recovery in margins.
Investment Summary
Every headline number this report produces, collected in one place before the analysis that derives them. All figures are computed live at page load, so this block reflects the market as of the moment you opened the page.
- Margins improve with simplification and cost savings.
- Prefillable syringes benefit from injectable drug growth.
- Infusion regulatory issues resolve.
- Portfolio actions unlock value.
- BD is a medtech supplier of syringes, infusion, and diagnostics.
- Simplification and margin improvement are central.
- Regulatory and execution risk are the main risks.
- Organic growth and operating margin are the key numbers.
- BD sells syringes, needles, IV catheters, infusion pumps, diagnostics, and biosciences tools.
- Its products are embedded in hospital workflows, generating recurring, consumable-driven revenue.
- The company is streamlining by separating its biosciences and diagnostics business.
- Infusion pump issues created a regulatory overhang in the past.
- The equity debate is how much growth and margin improvement the simplified portfolio delivers.
Executive Summary
BD has an entrenched position in hospital consumables and medication delivery, where safety and reliability matter more than price alone.
The company faced infusion pump quality and regulatory issues that consumed resources and depressed sentiment.
Portfolio actions aim to focus BD on higher-growth medical technology areas and improve margins.
Hospitals' capital budgets and procedure volumes influence demand, along with supply chain and inflation effects.
The realistic thesis: a durable, lower-growth medtech franchise with a self-help margin story, where execution and regulatory resolution drive valuation.
Industry & Market Backdrop
The broader competitive and macro environment BDX operates in — context a pure valuation table can't convey on its own.
Hospital staffing and cost pressures have shifted purchasing toward efficiency and automation.
Supply chain and input costs affected margins in recent years.
Regulatory oversight of infusion pumps and device quality remains strict.
Diagnostics volumes were affected by respiratory testing normalization.
Portfolio separations across the industry aim to unlock value.
Live Key Statistics
Pulled live from BriMindInvest's market-data pipeline at page load — the same feed that powers /analysis/BDX. Fields the pipeline doesn't return this load are omitted rather than shown blank.
Business Overview
Medical Essentials including syringes, needles, and catheters.
Connected Care including infusion pumps and patient monitoring.
BioPharma Systems providing prefillable syringes for drug makers.
Interventional and diagnostics-related products.
Segment Deep Dive
A closer look at each reporting segment individually, rather than treating the business as a single undifferentiated revenue line.
Core consumables with a large installed base and steady volume. Pricing power is modest, and reliability and safety features defend share.
Infusion pumps, software, and related disposables. Regulatory clearance and the installed base drive recurring revenue, with quality matters a key watch area.
Prefillable syringes for injectable drugs, including biologics and obesity drugs, offer growth. Interventional products serve procedures with higher growth.
Capital Allocation & Balance Sheet Philosophy
How management has historically chosen to deploy cash — buybacks, dividends, R&D, and acquisitions — and what that reveals about capital discipline.
Free cash flow supports dividends, debt reduction, and share repurchases.
Portfolio separations and divestitures aim to sharpen focus.
Capital investment is directed toward manufacturing and automation.
A long record of dividend increases is central to the investor case.
Management & Governance
Leadership, incentive alignment, and governance structure — factors that shape execution risk independent of the underlying business model.
Leadership is pursuing simplification and margin improvement.
Management has set targets for growth and margin expansion over multiple years.
Governance is conventional; review the proxy for details.
Regulatory remediation and execution in portfolio actions are watch items.
See exactly how we get BDX's fair-value range
| Method | Relevance | Implied Value |
|---|---|---|
| Our DCF Model | High | |
| Our P/E Based | Medium | |
| Our Book Value Based | Medium | |
| Graham Number | Medium | |
| ROIC Based | Medium | |
| FCF Yield Based | High |
Forecast Revenue and Free Cash Flow
5-Year Monte Carlo Simulation
Included with a subscription or a one-time purchase of this Becton Dickinson report:
- Fair value from 7 methods, weighted by relevance to this business
- 5-year financial forecast and DCF/earnings sensitivity grids
- Decomposed AI Score, Monte Carlo simulation, and institutional/analyst data
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
Bull Case vs. Bear Case
- Margins improve with simplification and cost savings.
- Prefillable syringes benefit from injectable drug growth.
- Infusion regulatory issues resolve.
- Portfolio actions unlock value.
- Steady hospital demand supports volume.
- Regulatory issues persist.
- Pricing pressure limits growth.
- Portfolio actions fail to deliver.
- Input costs rise.
- Hospital budgets tighten.
Related Reports
In-depth reports for other names in Becton Dickinson's comparable set.
4 catalysts and 4 risks we're tracking for BDX
| Catalyst | Expected Impact | Timeframe |
|---|---|---|
Included with a subscription or a one-time purchase of this Becton Dickinson report:
- Catalyst list, each tagged with expected impact and timing
- Risk register scored by probability and severity
- 4 key metrics to watch before the next earnings report
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
What Would Change Our Mind?
Specific, falsifiable triggers — not vague sentiment — that would move us toward or away from the bull case above.
- Margins rise as targeted
- Regulatory issues are resolved
- Growth accelerates in injectables
- Quality issues resurface
- Growth remains flat
- Margin targets are missed
Competitive Positioning
BD's moat is installed base, regulatory approvals, scale in manufacturing, and hospital relationships.
Medtronic, Baxter, ICU Medical, and Smiths Group compete in various categories.
Switching costs are meaningful for pumps and workflow-integrated products.
The vulnerability is quality issues and limited pricing power in commodity products.
Investor Decision Framework
A process for using this report, not a recommendation — how to weigh valuation, scenario spread, and your own risk tolerance.
- Own it if you want a stable, dividend-paying medtech with self-help potential.
- Skip it if you want higher growth.
- Track margin progress and regulatory updates.
The BriMindInvest Edge
Why this report is different from asking a general-purpose AI chatbot about the stock.
- Every valuation number on this page is computed live from current market data through our own DCF, scoring, and Monte Carlo engines — not summarized or paraphrased from other analysts' reports the way a general chatbot would.
- The relevance-weighted fair value, reverse-DCF market-implied growth, fundamentals-based Monte Carlo, and scenario tables above are proprietary calculations you cannot get by asking a general-purpose AI for "BDX fair value" — those answers come from web summaries of other people's price targets, not a live, disclosed-assumption model.
- Our 1-year price-target model has a real, published backtest (see Model Track Record above where covered) — we show our work and our error rate rather than asserting accuracy.
- Numbers here are refreshed every time you load the page, not cached from a training cutoff months or years in the past.
Data Sources & Methodology
Valuation, price, and financial-statistics data in this report are fetched live from our production market-data pipeline (Yahoo Finance and Finnhub) at the time you loaded this page. The AI Score is a percentile ranking against our full covered stock universe, recomputed nightly. The fundamentals-based Monte Carlo and Bull/Base/Bear scenarios randomize growth rate, discount rate, and terminal growth around the same disclosed DCF assumptions used in the valuation table — they are not derived from resampled historical stock returns. The secondary historical-volatility simulation (2,000 bootstrap paths, seeded for reproducibility) uses the stock's own historical monthly returns and is shown separately because it measures a different thing (volatility) than the fundamentals-based model (intrinsic value).
This report is for informational and educational purposes only and does not constitute financial, investment, or tax advice, or a recommendation to buy or sell any security. All valuation models, price targets, and simulations are estimates based on historical and current data; actual results will differ, potentially substantially. Investing involves risk, including loss of principal. See our full Methodology and Disclaimer.
Free vs. Premium: What You're Getting
- Narrative overview and general bull/bear framing
- Headline price and basic company facts
- No live valuation model, AI Score, or forecast table
- Relevance-weighted fair value range and reverse-DCF market-implied growth
- 5-year financial forecast, DCF sensitivity grid, and Bull/Base/Bear scenario table
- Fundamentals-based Monte Carlo and decomposed AI Score with sub-factor components
- Real, published backtested accuracy where BDX is in our coverage set
Glossary of Key Terms
Plain-English definitions for the terms used throughout this report, for readers newer to equity valuation.
Frequently Asked Questions
Unlock Full AI-Powered Analysis
Get AI prediction signals, unlimited stock comparisons, portfolio analytics, and personalized watchlists — free for 14 days, no credit card required.
14-day free trial · No credit card required · Cancel anytime
Not ready to sign up? Get one free email a week instead.